102 results on '"Bretti S"'
Search Results
2. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)
- Author
-
Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E., Banna, G, Di Maio, M, Follador, A, Collovà, E, Menis, J, Novello, S, Bria, E, Airoldi, M, Amoroso, D, Ardizzoia, A, Aurilio, G, Bajetta, E, Ballardini, P, Barbieri, F, Barletta, E, Balzelloni, M, Basso, U, Bernardini, I, Boni, C, Bordin, V, Bretti, S, Bronte, G, Brunetti, C, Buti, S, Capanna, L, Colombo, A, Condemi, G, Cortinovis, D, Dambrosio, M, Di Fonzo, C, Di Lucca, G, Dima, G, Falzetta, A, Favaretto, A, Ferraù, F, Garetto, L, Gebbia, V, Genestreti, G, Gentile, A, Giovanardi, F, Labianca, R, Lorusso, V, Mantovani, G, Martelli, O, Massari, F, Mazzoli, M, Michetti, G, Mordenti, P, Mucciarini, C, Munao, S, Nacci, A, Pogliani, C, Procopio, G, Riccardi, F, Rizzato, S, Rossi, A, Rosti, G, Russo, P, Saladino, T, Salesi, N, Santangelo, D, Sava, T, Savarino, A, Spinnato, F, Tiseo, M, Tomassi, O, Tondulli, L, Tonini, G, Turano, S, Valerio, M, Verderame, F, Zanelli, F, Zanon, E, Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, and Zanon E.
- Abstract
Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians. Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen.
- Published
- 2011
3. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide
- Author
-
Papaldo, P., Lopez, M., Cortesi, Enrico, Cammilluzzi, E., Antimi, M., Terzoli, E., Lepidini, G., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Nistico, C., Carlini, P., Conti, F., Di Lauro, L., Botti, C., Vitucci, C., Fabi, A., Giannarelli, D., Marolla, P., Di Maio, M., Perrone, F., Gallo, C., Iaffaioli, R. V., Manzione, L., Piantedosi, F. V., Cigolari, S., Illiano, A., Barbera, S., Robbiati, S. F., Piazza, E., Ianniello, G. P., Frontini, L., Veltri, E., Castiglione, F., Rosetti, F., De Maio, E., Maione, P., Gridelli, C., Rossi, A., Barletta, E., Barzelloni, M. L., Signoriello, G., Bilancia, D., Dinota, A., Rosati, G., Germano, D., Lamberti, A., Pontillo, V., Brancacio, L., Crispino, C., Esposito, M., Battiloro, C., Tufano, G., Cioffi, A., Guardasole, V., Angelini, V., Guidetti, G., Renda, F., Romano, F., Volpintesta, A., Sannicolo, M., Filipazzi, V., Esani, G., Gambaro, A., Ferrario, S., Tinessa, V., Caprio, M. G., Zonato, S., Cabiddu, M., Raina, A., D'Aprile, M., Pistillucci, G., Porcile, G., Ostellino, O., Vinante, O., Azzarello, G., Gebbia, V., Borsellino, N., Testa, A., Gasparini, G., Morabito, A., Gattuso, D., Romito, S., Carrozza, F., Fava, S., Calcagno, A., Grimi, E., Bertetto, O., Ciuffreda, L., Parello, G., Maiorino, L., Santoro, A., Santoro, M., Failla, G., Aiello, R. A., Bearz, A., Sorio, R., Scalone, S., Clerici, M., Bollina, R., Belloni, P., Sacco, C., Sibau, A., Adamo, V., Altavilla, G., Scimone, A., Spatafora, M., Bellia, V., Hopps, M. R., Monfardini, S., Favaretto, A., Stefani, M., Corradini, G. M., Pavia, G., Scagliotti, G., Novello, S., Selvaggi, G., Tonato, M., Darwish, S., Michetti, G., Belometti, M. O., Labianca, R., Quadri, A., De Marinis, F., Migliorino, M. R., Martelli, O., Colucci, G., Galetta, D., Giotta, F., Isa, L., Candido, P., Rossi, N., Calandriello, A., Ferrau, F., Malaponte, E., Barni, S., Cazzaniga, M., Gebbia, N., Valerio, Mr, Belli, M., Colantuoni, G., Capuano, M. A., Angiolillo, M., Sollitto, F., Ardizzoia, A., Luporini, G., Locatelli, M. C., Pari, F., Aitini, E., Pedicini, T., Febbraro, A., Zollo, C., Di Costanzo, F., Bartolucci, R., Gasperoni, S., Gaion, F., Palazzolo, G., Galligioni, E., Caffo, O., Cortesi, E., D'Auria, G., Curcio, C., Vasta, M., Bumma, C., Celano, A., Bretti, S., Nettis, G., Anselmo, A., Mattioli, R., Aschelter, A., and Foa, P.
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Indazoles ,Filgrastim ,Cyclophosphamide ,medicine.medical_treatment ,Breast Neoplasms ,Gastroenterology ,Disease-Free Survival ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Survival rate ,Aged ,Epirubicin ,Chemotherapy ,business.industry ,Lonidamine ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,Recombinant Proteins ,Granulocyte colony-stimulating factor ,Surgery ,Survival Rate ,Oncology ,chemistry ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
Purpose: Lonidamine (LND) can enhance the activity of anthracyclines in patients with metastatic breast cancer. A multicenter, prospective, randomized trial was designed to determine whether the association of LND with high-dose epirubicin plus cyclophosphamide (EC) could improve disease-free survival (DFS) in patients with early breast cancer (BC) compared with EC alone. Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity. Patients and Methods: From October 1991 to April 1994, 506 patients with stage I/II BC were randomly assigned to four groups: (A) epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on day 1 every 21 days for four cycles (124 patients); (B) EC plus LND 450 mg/d administered orally (125 patients); (C) EC plus G-CSF administered subcutaneously (129 patients); (D) EC plus LND plus G-CSF (128 patients). Results: Median follow-up was 55 months. Five-year DFS rate was similar for LND (B+D groups; 69.6%) versus non-LND arms (A+C groups; 70.3%) and G-CSF (C+D groups; 67.2%) versus non–G-CSF arms (A+B groups; 72.9%). Five-year overall survival (OS) was comparable in LND (79.1%) versus non-LND arms (81.3%) and in G-CSF (80.6%) versus non–G-CSF arms (79.6%). DFS and OS distributions in LND and G-CSF arms did not change according to tumor size, node, receptor, and menopausal status. G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity (98.1% v 95.5% for C+D and A+B groups, respectively). Conclusion: EC is active and well tolerated in patients with early breast cancer. The addition of LND or G-CSF does not improve DFS or OS.
- Published
- 2003
4. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey
- Author
-
Natoli, C., Brocco, D., Sperduti, I., Nuzzo, A., Tinari, N., De Tursi, M., Grassadonia, A., Mazzilli, L., Iacobelli, S., Gamucci, T., Vici, P., Study, Group, Adamo, V., Airoldi, M., Amoroso, D., Angelini, F., Angiolini, C., Angiolucci, G., Ardizzoia, A., Baldini, E., Ballardini, P., Barni, S., Barone, C., Battelli, N., Bernardi, D., Bianchetti, S., Bianco, N., Biglia, Nicoletta, Bilancia, D., Biti, G., Boni, C., Bordonaro, R., Botta, M., Bretti, S., Brunello, A., Brunetti, C., Bruno, D., Bucci, E., Buzzoni, R., Cagossi, K., Cappelletti, C., Cappuzzo, F., Cardillo, F., Carroccio, R., Cascinu, S., Cavanna, L., Cianchetti, E., Clerico, M., Contu, A., Corsi, D., Cortesi, L., Cretella, E., Crispino, S., Di Lieto, M., Di Lullo, L., Durini, E., Fabi, A., Failla, G., Fattorusso, S., Ferraù, F., Ferro, A., Ficorella, C., Fogazzi, G., Foglietta, J., Francini, G., Fusco, O., Gennari, A., Ghiani, M., Gianni, L., Giordano, M., Giotta, F., Giuliani, R., Gori, S., Graiff, C., Guarneri, V., Guarneri, D., Guglielmi, F., Landriscina, M., Laudadio, L., Lombardo, M., Longo, F., Macellari, G., Madeddu, C., Magnanini, S., Maiorino, L., Mangiameli, A., Marini, G., Massidda, B., Mattioli, R., Michelotti, A., Molino, A., Montesarchio, V., Morale, A., Murgo, R., Naso, G., Natale, D., Orditura, M., Orrù, S., Pace, R., Palazzo, A., Palma, F., Pancotti, A., Pandoli, G., Papaldo, P., Parisi, A. M., Passalacqua, R., Pellegrino, A., Perrucci, B., Proietti, E., Recchia, F., Riccardi, F., Rispoli, A. I., Rocca, A., Romaniello, I., Rossetti, R., Rossi, D., Rosti, G., Ruggeri, E. M., Russo, A., Savarino, A., Savastano, C., Scognamiglio, G., Scognamiglio, M., Seminara, P., Serrachini, S., Sidoti, V., Silva, R. R., Surace, G., Tomao, S., Tonini, G., Trenta, P., Turazza, M., Valenza, R., Veltri, E., Zampa, G., Zaniboni, A., Zanirato, S., C, Natoli, D, Brocco, I, Sperduti, A, Nuzzo, N, Tinari, M, De Tursi, A, Grassadonia, L, Mazzilli, S, Iacobelli, T, Gamucci, P, Vici, Study Group, 'FOLLOW-UP', and Orditura, Michele
- Subjects
Oncology ,breast cancer ,Follow-up ,survey ,Medical Oncology ,law.invention ,Randomized controlled trial ,law ,Aged ,Breast Neoplasms ,Female ,Follow-Up Studies ,Health Care Surveys ,Humans ,Italy ,Middle Aged ,Secondary Prevention ,Guideline Adherence ,Breast Tumors ,Medicine and Health Sciences ,Web based survey ,Multidisciplinary ,Pharmaceutics ,Surgical Oncology ,Cancer Therapy ,Medicine ,medicine.symptom ,Disease staging ,Research Article ,medicine.medical_specialty ,Adjuvant Cancer Chemotherapy ,Science ,MEDLINE ,Asymptomatic ,Breast cancer ,Drug Therapy ,Internal medicine ,medicine ,Cancer Detection and Diagnosis ,Chemotherapy ,Modalities ,business.industry ,Cancers and Neoplasms ,medicine.disease ,Blood chemistry ,Women's Health ,Clinical Medicine ,business - Abstract
PurposeBreast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice.MethodsReferents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year.ResultsBetween February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.ConclusionsOur survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.
- Published
- 2014
5. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey
- Author
-
Natoli, C, Adamo, V, Airoldi, M, Amoroso, D, Angelini, F, Angiolini, C, Angiolucci, G, Ardizzoia, A, Baldini, E, Ballardini, P, Barni, S, Barone, C, Battelli, N, Bernardi, D, Bianchetti, S, Bianco, N, Biglia, N, Bilancia, D, Biti, G, Boni, C, Bordonaro, R, Botta, M, Bretti, S, Brunello, A, Brunetti, C, Bruno, D, Bucci, E, Buzzoni, R, Cagossi, K, Cappelletti, C, Cappuzzo, F, Cardillo, F, Carroccio, R, Cascinu, S, Cavanna, L, Cianchetti, E, Clerico, M, Contu, A, Corsi, D, Cortesi, L, Cretella, E, Crispino, S, Di Lieto, M, Di Lullo, L, Durini, E, Fabi, A, Failla, G, Fattorusso, S, Ferraù, F, Ferro, A, Ficorella, C, Fogazzi, G, Foglietta, J, Francini, G, Fusco, O, Gennari, A, Ghiani, M, Gianni, L, Giordano, M, Giotta, F, Giuliani, R, Gori, S, Graiff, C, Guarneri, V, Guarneri, D, Guglielmi, F, Landriscina, M, Laudadio, L, Lombardo, M, Longo, F, Macellari, G, Madeddu, C, Magnanini, S, Maiorino, L, Mangiameli, A, Marini, G, Massidda, B, Mattioli, R, Michelotti, A, Molino, A, Montesarchio, V, Morale, A, Murgo, R, Naso, Giuseppe, Natale, D, Orditura, M, Orrù, S, Pace, R, Palazzo, Antonella, Palma, F, Pancotti, A, Pandoli, G, Papaldo, P, Parisi, Am, Passalacqua, R, Pellegrino, A, Perrucci, B, Proietti, E, Recchia, F, Riccardi, F, Rispoli, Ai, Rocca, A, Romaniello, I, Rossetti, R, Rossi, D, Rosti, G, Ruggeri, Em, Russo, A, Savarino, A, Savastano, C, Scognamiglio, G, Scognamiglio, M, Seminara, Patrizia, Serrachini, S, Sidoti, V, Silva, Rr, Surace, G, Tomao, Silverio, Tonini, G, Trenta, P, Turazza, M, Valenza, R, Veltri, E, Zampa, G, Zaniboni, A, and Zanirato, S.
- Published
- 2014
6. Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey
- Author
-
MERCADANTE, S, ROILA, F, BERRETTO, O, LABIANCA, R, CASILINI, S, BOTTERO, G, TROVA, V, CASCINU, S, DI VITO, F, LORUSSO, V, TROCCOLI, G, ENDRIZZI, L, DANIELE, B, MARTONI, A, MARINI, G, VITELLO, S, ROMITO, S, SBALZARINI, G, SERRAVEZZA, G, MANENTE, P, MOLICA, S, PALAZZO, S, PRANTERA, T, MERLANO, M, DI GIROLAMO, G, AMADORI, D, SOBRERO, A, ALGERI, R, BRETTI, S, GRECO, E, D'APRILE, M, FORCIGNANO, C, BONETTI, A, AITINI, E, PIAZZA, E, PIVA, L, TABBIADON, D, CARTENI', G, CATALANO, G, ALABISO, O, LANDRISCINA, G, DOGLIOTTI, L, FILIPPELLI, G, BERTE', R, RICCI, S, MANZIONE, L, IACONO, C, MARANGOLO, M., GEBBIA, Nicolo', PALMERI, Sergio, MERCADANTE, S, ROILA, F, BERRETTO, O, LABIANCA, R, CASILINI, S, BOTTERO, G, TROVA, V, CASCINU, S, DI VITO, F, LORUSSO, V, TROCCOLI, G, ENDRIZZI, L, DANIELE, B, MARTONI, A, MARINI, G, VITELLO, S, ROMITO, S, SBALZARINI, G, SERRAVEZZA, G, MANENTE, P, MOLICA, S, PALAZZO, S, PRANTERA, T, MERLANO, M, DI GIROLAMO, G, AMADORI, D, SOBRERO, A, ALGERI, R, BRETTI, S, GRECO, E, D'APRILE, M, FORCIGNANO, C, BONETTI, A, AITINI, E, PIAZZA, E, PIVA, L, TABBIADON, D, CARTENI', G, CATALANO, G, ALABISO, O, LANDRISCINA, G, DOGLIOTTI, L, GEBBIA, N, PALMERI, S, FILIPPELLI, G, BERTE', R, RICCI, S, MANZIONE, L, IACONO, C, and MARANGOLO, M
- Subjects
Adult ,Male ,medicine.medical_specialty ,Settore MED/06 - Oncologia Medica ,Cross-sectional study ,Pain medicine ,MEDLINE ,Pain ,Severity of Illness Index ,Neoplasms ,Oncology Service, Hospital ,Epidemiology ,Severity of illness ,medicine ,Prevalence ,Humans ,Aged ,Aged, 80 and over ,Primary Health Care ,business.industry ,Cancer pain,Epidemiology,Opioids ,Nursing research ,Physicians, Family ,Middle Aged ,Large sample ,Analgesics, Opioid ,Cross-Sectional Studies ,Oncology ,Italy ,Family medicine ,Health Care Surveys ,Physical therapy ,Female ,Cancer pain ,business - Abstract
The aim of this national cross-sectional survey was to draw information on pain prevalence and intensity from a large sample of patients who were admitted to oncologic centres for different reasons and to evaluate the pain treatment and possible influencing factors.A total of 2,655 patients completed the study. Nine hundred and one patients (34%) reported pain.Higher pain levels were observed in inpatients, in the presence of bone metastases, and with low levels of Eastern Cooperative Oncology Group status. The number of patients receiving strong opioids increased with the highest levels of pain. However, a significant part of patients with moderate-severe pain were not receiving appropriate medication, patients being predominantly administered non-opioid drugs. General practitioners' attitudes did not negatively influence the opioid prescription.The results of this survey indicate a need for continuing educational and informative program in pain management for oncologists and more generally for any physician dealing with cancer patients.
- Published
- 2008
7. LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG A SUBSET OF PRIMARY LUNG CANCER WITH POOR PROGNOSIS
- Author
-
Filosso, Pier Luigi, Ruffini, Enrico, Asioli, Sofia, Bretti, S., Macri, L., and Oliaro, Alberto
- Published
- 2009
8. CLINICAL EVALUATION STUDY OF PRESENTATION, CLINICAL EVOLUTION, INCIDENCE OF SKELETAL COMPLICATIONS AND TREATMENTS OF BONE METASTASES: PRELIMINARY DATA
- Author
-
Loidoris, A, Ciuffreda, L, Berruti, A, Tucci, M, Dongiovanni, D, Ortega, C, Comandone, A, Bretti, S, Falco, P, Faggiuolo, R, Trotti, Ab, Torazzo, R, Ottaviani, D, Ferracini, Riccardo, Satolli, Ma, Testore, F, and Bertetto, O.
- Published
- 2009
9. Supportive care in patients with advanced non-small-cell lung cancer
- Author
-
DI MAIO, Massimo, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, De Maio, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolò, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, V, Altavilla, G, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, Giorgio Vittorio, Novello, Silvia, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, De Marinis, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferraù, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, Di Costanzo, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nisticò, C, Aschelter, A, Foa, P., DI MAIO, M, Perrone, F, Gallo, Ciro, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, and Gridelli, C.
- Subjects
Adult ,Male ,concomitant drugs ,Cancer Research ,medicine.medical_specialty ,Aging ,Palliative care ,Lung Neoplasms ,medicine.medical_treatment ,Vinorelbine ,Vinblastine ,Deoxycytidine ,Clinical ,Quality of life ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,polypharmacotherapy ,medicine ,Humans ,Lung cancer ,Survival rate ,Aged ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,Chemotherapy ,Performance status ,business.industry ,Palliative Care ,Middle Aged ,medicine.disease ,Gemcitabine ,Surgery ,Survival Rate ,supportive care ,lung cancer ,Oncology ,Concomitant ,Quality of Life ,Antiemetics ,Female ,Cisplatin ,business ,medicine.drug - Abstract
The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.
- Published
- 2004
10. Supportive care in patients with advanced non small cell lung cancer
- Author
-
DI MAIO, M, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolo, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, Vincenzo, Altavilla, Giuseppe, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, G, Novello, S, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, DE MARINIS, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferrau, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, DI COSTANZO, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nistico, C, Aschelter, A, and Foa, P.
- Published
- 2003
11. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
- Author
-
Gridelli, C, Perrone, F, Gallo, C, Rossi, A, Scognamiglio, F, Monfardini, S, Ianniello, Gp, Tinessa, V, Caprio, Mg, Santoro, A, Maiorino, L, Santoro, M, Brancaccio, L, Crispino, C, Cigolari, S, DI LANNO, M, Angelini, V, Manzione, L, Bilancia, D, Dinota, A, Failla, G, Aiello, Ra, Tralongo, P, Figoli, F, Zuccarino, L, Pedicini, T, Febbraro, A, Zollo, C, Frontini, L, Zonato, S, Azzarello, G, Vinante, O, Castiglione, F, Porcile, G, Bearz, A, Sorio, R, Tonato, M, Darwish, S, Veltri, E, D'Aprile, M, Curcio, C, Vasta, M, Clerici, M, Luporini, G, Farris, A, Alicicco, Mg, Bretti, S, Bumma, C, Ionta, Mt, Massidda, B, Adamo, Vincenzo, Altavilla, Giuseppe, Stefani, M, Michetti, G, Iaffaioli, Rv, Marzano, N, Favaretto, A, Murtas, S, Nascimbene, C, Nistico, C, Robbiati, Sf, Strada, Mr, Belli, M, Loizzi, M, Bandera, M, Bochicchio, Am, Piazza, E, Foladore, S, Giura, R, Gualtieri, G, Barni, S, Cariello, A, Mattioli, R, Pazzola, A, Gioga, G, Puxeddu, G, Bartolucci, R, Graiff, C, DEL CONTE, G, Farriniello, Ga, Mauri, F, Corradini, Gm, Capuano, Ma, Carrozza, F, and Gianni, W.
- Published
- 1999
12. Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes.
- Author
-
Donadio, M., Ardine, M., Berruti, A., Beano, A., Bottini, A., Mistrangelo, M., Bonardi, S., Castiglione, F., Generali, D., Polimeni, M. A., Bretti, S., Alabiso, O., and Bertetto, O.
- Subjects
CANCER patients ,ANTHRACYCLINES ,BREAST cancer ,METASTASIS ,CISPLATIN - Abstract
Background: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is challenging. This study evaluated the activity and safety of a combination of cisplatin and capecitabine in this setting. Patients and Methods: Thirty-nine consecutive patients entered the study. All had experienced failures or relapse after previous treatment with anthracyclines and taxanes plus/minus other chemotherapeutic regimens. The present treatment consisted of intravenous cisplatin 20 mg/m
2 every week for 6 weeks, followed by 1 week of rest, and oral capecitabine 1,000 mg/m2 twice daily for 14 days, followed by a 7-day rest period. Results: Objective response was obtained in 14 patients (35.9%), with complete remission in 3 (7.7%). Median time to progression was 5.2 months and survival was 10.9 months in the entire population and 8.7 and 16.5 months in the responding patients, respectively. The dose-limiting toxicity for the regimen was leucopenia, while gastrointestinal discomfort was the most frequent cause of capecitabine reduction or delay. Conclusions: The cisplatin and capecitabine combination regimen is active and manageable. It seems to be non-cross resistant to anthracyclines and taxanes. Copyright © 2005 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
13. Multimodal management of stages III–IVa malignant thymoma
- Author
-
Bretti, S., Berruti, A., Loddo, C., Sperone, P., Casadio, C., Tessa, M., Ardissone, F., Gorzegno, G., Sacco, M., Manzin, E., Borasio, P., Sannazzari, G.L., Maggi, G., and Dogliotti, L.
- Subjects
- *
DISEASES , *SURGICAL excision , *COMBINED modality therapy , *DRUG therapy , *RADIOTHERAPY - Abstract
Purpose: The optimal therapy for locally advanced malignant thymoma is controversial. We review our experience with a multimodal approach in 63 consecutive cases. Patients and methods: Forty-three patients had stage III and 20 stage IVa disease. Surgery with radical intent was initially performed in 30 cases, while 33 cases not amenable to radical surgery underwent neoadjuvant treatment (radiotherapy in 8 and chemotherapy in 25) before surgical reassessment. All patients, whether or not surgically resected, received radiation therapy. Results: Radical resection (RR) was performed in 20 patients ab initio (all stage III) and in 12 patients after neoadjuvant treatment (eight stage III and four stage IVa). With the addition of patients radically operated with neoadjuvant treatment, the radical resection rate increased from 46 to 65% in stage III patients, and from 0 to 20% in those with stage IVa disease, respectively. Radical surgery was associated with longer progression free survival and overall survival according to both univariate analysis (
P<0.001 and 0.01, respectively) and multivariate analysis after adjustment for age, gender, histology and disease stage (P<0.001 and <0.02, respectively). Progression free survival (median 56.9 months) was slightly lower in patients undergoing radical surgery after neoadjuvant approaches than in those radically resected ab initio (median not achieved), but overall survival (median not achieved) was similar in both groups. Subtotal surgical resection promoted complete response to subsequent radiation therapy. This condition significantly correlated with a better outcome. Conclusions: Complete surgical resection is an independent prognostic parameter in locally advanced thymoma treated with a multimodal approach. Preoperative treatment to increase the complete resection rate could improve the overall survival of these patients. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
14. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
- Author
-
Parra, H S, Tixi, L, Latteri, F, Bretti, S, Alloisio, M, Gravina, A, Lionetto, R, Bruzzi, P, Dani, C, Rosso, R, Cosso, M, Balzarini, L, Santoro, A, and Ardizzoni, A
- Published
- 2001
- Full Text
- View/download PDF
15. Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.
- Author
-
Comoglio, P. M., Prat, Maria, and Bretti, S.
- Subjects
ROUS sarcoma ,IMMUNITY ,LYMPHOCYTES ,T cells ,TUMORS ,LABORATORY mice - Abstract
Previous work from this laboratory has shown that preimmunization of syngeneic hosts with Rous sarcoma virus (RSV)-transformed cells elicits a strong immune response against the growth of transplantable RSV sarcomas, mediated by T lymphocytes expressing the surface phenotype of helper cell precursors (Prat, Di Renzo & Comoglio, 1983). This paper shows that anti-tumour immunity may be elicited in tumour-bearing animals by triggering an experimentally pre-amplified T-helper cell population at the site of tumour growth. Mice were treated with cyclophosphamide (which inactivates suppressor T cells) followed by skin sensitization to trinitrochlorobenzene (TNCB) according to a protocol that has been shown to induce an appreciably amplified generation of trinitrophenyl (TNP)-reactive helper T cells (Fujiwara et al., 1984). Five weeks after TNCB painting, mice were transplanted s.c. with a lethal dose of RSV-induced syngeneic sarcoma cells; the injection at the tumour site of TNCB induced the regression of the tumour in mice in which the TNP-helper cell population has been amplified, but not in controls, including those injected with a non-related hapten or sensitized to TNCB without inactivation of suppressors. [ABSTRACT FROM AUTHOR]
- Published
- 1985
16. Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy
- Author
-
Roila, Fausto, Ruggeri, Benedetta, Ballatori, Enzo, Patoia, Lucio, Palazzo, Salvatore, Colucci, Giuseppe, Di Costanzo, Francesco, Cascinu, Stefano, Labianca, Roberto, Sobrero, Alberto, Cortesi, E., Bressi, C., Ferraldeschi, R., Mazzoli, M., Evangelista, M.L., Di Fonzo, C., Cigolari, S., Angelini, V., Cioffi, A., Guardasole, V., Zarra, E., Tonato, M., Betti, M., Marrocolo, F., Bon-ciarelli, V., Cetto, G., Silingardi, V., Cognetti, F., Beretta, G., Pessi, A., Mosconi, S., Milesi, L., Bertetto, O., Malacarne, P., Marzola, M., Margutti, G., Modenesi, C., Manente, P., Comandone, A., Oliva, C., Berniolo, P., Cutin, S. Chiadò, Luporini, G., Colucci, G., Recaldin, E., Nicodemo, M., Picece, V., Turaz-za, M., Ferrazzi, E., Solina, G., Rosati, G., Rossi, A., Manzione, L., Sozzi, P., Fornarini, G., Lavarello, A., Catalano, G., Giordani, P., Alessandroni, P., Troccoli, G., Ramus, G. Vietti, Tonda, L., Sirgiovanni, M.P., Iannello, G. P., Tinessa, V., Ruggiero, A, Palazzo, S., Barni, S., Mandalà, M., Cremonesi, M., Porcile, G., Destefanis, M., Testore, F., Carteni, G., Daniele, B., Volta, C., Ferraù, F., Zaniboni, A., Marchetti, P., Citone, G., Cefaro, G. Ausili, Iacono, C., Musi, M., Mozzicafreddo, A., Imperiale, F. Nigro, Filippelli, G., Sciacca, V., D'Aprile, M., Isa, L., Recchia, F., Spada, S., Cascinu, S., Carroccio, R., Mustacchi, G., Ceccherini, R., Chetrì, M., Rizzo, P., Botturi, M., Marchei, P., Bretti, S., Montalbetti, L., Reguzzoni, G., Massidda, B., Ionta, M.T., Cruciani, G., Prosperi, A., Mantovani, G., Sidoti, V., Peta, A., Greco, E., Cicero, G., Sobrero, A., Marsilio, P., Vigevani, E., Rimondi, G., Gebbia, V., Nuzzo, A., Biondi, E., Caroti, C., D'Amico, M., Tuveri, G., Pieri, G., Enrici, R. Maurizi, Tonini, G., Santini, D., Iannone, T., Pizza, C., Belli, M., Del Prete, S., Pizza, C., Trevisonne, R., Serlenga, M., Laricchiuta, R., Lacava, V., Bumma, C., Roselli, M., Verderame, F., Mascia, V., Perrone, D., Prantera, T., Venuta, S., Nastasi, G., Bortolussi, V., and Lembo, A.
- Abstract
Aims and Background Rarely are conclusions from clinical trials summarized in international consensus conferences and promptly transferred to patient care. The adjuvant therapy for colorectal cancer used in daily clinical practice in Italy is described and compared with the recommendations of the 1990 NIH Consensus Conference.Patients and Methods We audited prescriptions of adjuvant systemic therapies for Italian colorectal cancer patients in 82 centers during a fixed one-week period.Results Among 434 patients receiving adjuvant chemotherapy there were 139 (42.5%) colon cancer patients with N- and 169 (51.7%) with N+ regional nodal involvement. Treatment at academic centers, a young age, T4 and a low total number of lymph nodes removed at surgery were the factors potentially justifying the decision for adjuvant chemotherapy in stage II colon cancer patients. The most common chemotherapy used was a bolus of 5-fluorouracil/folinic acid for 6 months (75.8%). Adjuvant radiotherapy was not administered to 37 (38.5%) of 96 patients with stage II and III rectal cancer.Conclusions The study shows that a substantial proportion of patients on adjuvant treatment at a certain time point in a large enough sample of Italian centers are stage II (potential over-treatment) and that an under-treatment of stage II and III rectal cancer patients (lack of radiotherapy) occurs too often in daily clinical practice in this country.
- Published
- 2005
- Full Text
- View/download PDF
17. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas
- Author
-
Prat, M., Bretti, S., Amedeo, M., Landolfo, Santo Giuseppe, and Comoglio, Paolo
- Subjects
Graft Rejection ,Mice, Inbred BALB C ,T-Lymphocytes ,Immunology ,Immunization, Passive ,Antibodies, Monoclonal ,T-Lymphocytes, Helper-Inducer ,Interferon-gamma ,Mice ,Avian Sarcoma Viruses ,Animals ,Immunology and Allergy ,Female ,Sarcoma, Experimental ,Neoplasm Transplantation - Abstract
Previous work has shown that immunization of syngeneic mice with v-src-induced sarcomas gives rise to specific protection against a lethal dose of v-src-transformed fibroblasts. This immune response is mediated by Lyt-1+, Lyt-2,3+ T lymphocytes, with no apparent involvement of cytotoxic T cells, as shown in Winn-type assays. Immune cells mediating tumor rejection in this system have now been further characterized, and it was found that L3T4+ T lymphocytes alone provided full protection against v-src-induced sarcomas. Moreover, the role of interferon-gamma (IFN-gamma) in the tumor rejection was analyzed. A monoclonal antibody directed against this lymphokine was able to reverse the protective effect displayed by immune T lymphocytes, by eliciting highly effective T suppressor cells. It was thus concluded that T cells with L3T4 surface marker are the main thing responsible for the adoptive immunity in this tumor system, and the activity of these cells is positively modulated by lymphokines such as IFN-gamma.
- Published
- 1987
18. Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients
- Author
-
Bretti, S., Berruti, A., Gorzegno, G., Ciura, P. La, Paze, E., Celano, A., Grecchi, G., Perroni, D., Bumma, C., and Dogliotti, L.
- Published
- 1996
- Full Text
- View/download PDF
19. Interleukin-3 in vivo: kinetic of response of target cells
- Author
-
Aglietta, M, Sanavio, F, Stacchini, A, Morelli, S, Fubini, L, Severino, A, Pasquino, P, Volta, C, Bretti, S, and Tafuto, S
- Abstract
Human recombinant interleukin-3 (IL-3; Sandoz AG, Basel, Switzerland) was administered for 7 days to patients with neoplastic disease and normal hematopoiesis. The purpose of the study was to assess IL-3 toxicity, to identify target cells, to define their kinetics of response at different dose levels, and to determine if IL-3 in vivo increased the sensitivity of bone marrow (BM) progenitors to the action of other hematopoietic growth factors. A total of 21 patients entered the study; the dosage ranged from 0.25 to 10 micrograms/kg/d. The effect on peripheral blood cells during treatment showed no significant changes in the number of platelets, erythrocytes, neutrophils, or lymphocytes (and their subsets). A mild monocytosis and basophilia occurred. Eosinopenia, present in the first hours of treatment, was followed by a dose-and time-dependent eosinophilia. IL-3 treatment affected BM cell proliferation by increasing the percentage of BM progenitors engaged in the S-phase of the cell cycle. The effect was dose dependent, with the various progenitors showing different degrees of sensitivity. The most sensitive progenitors were the megakaryocyte progenitors (colony-forming unit-megakaryocyte), then the erythroid progenitors (burst-forming unit-erythroid), and finally the granulo- monocyte progenitors (colony-forming unit-granulocyte-macrophage) whose proliferative activity was stimulated at the higher doses of IL-3. Only a slight increase in the proliferative activity of myeloblasts, promyelocytes, and myelocytes was observed, whereas the activity of erythroblasts was unchanged. The priming effect was such that BM progenitors, purified from patients treated with IL-3, produced more colonies in vitro in the presence of granulocyte colony-stimulating factor (G-CSF; granulocyte colonies), IL-5 (eosinophil colonies), and granulocyte-macrophage CSF (GM-CSF; predominantly eosinophil colonies). These data indicate that even in vivo IL-3 acts essentially as a primer for the action of other cytokines. Therefore, optimum stimulus of myelopoiesis will require either endogenous or exogenous late-acting cytokines such as G-CSF, erythropoietin, GM-CSF, and IL-6 for achieving fully mature cells in peripheral blood. If exogenous cytokines are used with IL-3, it is likely that G-CSF will yield more neutrophils, whereas GM-CSF may enhance eosinophils, monocytes, and neutrophils. Attention to the clinical relevance of each cell type will be necessary and should determine the selection of the combination of cytokines.
- Published
- 1993
- Full Text
- View/download PDF
20. The Monoclonal Antibody-defined CAR-3 Antigen is a Serological Marker Associated with Pancreatic Carcinoma
- Author
-
Prat, M., Medico, E., Piantino, P., Bretti, S., Rossini, F.P., and Comoglio, P.M.
- Abstract
The monoclonal antibody-defined CARS antigen is a new carcinoma associated marker which is expressed on a mucin-like molecule. Serum concentrations of CARS were assayed in 181 patients with carcinomas of different organs, 20 patients with non-carcinomatous malignancies, 123 patients with inflammatory diseases and 150 healthy controls. Serum levels of CARS were significantly increased in 51% of the patients with pancreatic carcinomas, in 60% of patients with biliary tract carcinomas and in about 15% of the patients with carcinomas of the digestive apparatus. Sera from patients with breast carcinomas were negative, as well as sera from patients with melanomas or sarcomas. CAR-3 values in samples from patients with chronic pancreatitis were constantly negative, as were samples from healthy donors. Significant concentrations of CAR-3 were detected in 20% of the sera from patients with acute pancreatitis and in 15% of the sera from patients with cirrhosis. Because of its high specificity for pancreatic carcinomas compared to chronic pancreatitis, CARS seems a promising marker for distinguishing between neoplastic and chronic inflammatory diseases of the pancreas, whose differential diagnosis is difficult.
- Published
- 1988
- Full Text
- View/download PDF
21. Inhibition of experimental metastasis of murine fibrosarcoma cells by oligopeptide analogues to the fibronectin cell-binding site
- Author
-
M. Rustici, P. Neri, Paolo M. Comoglio, Filippo G. Giancotti, Bretti S, Luisa Lozzi, and Guido Tarone
- Subjects
Cancer Research ,Lung Neoplasms ,Fibrosarcoma ,Enzyme-Linked Immunosorbent Assay ,Peptide ,Cell Line ,Mice ,Receptors, Fibronectin ,In vivo ,Cell Adhesion ,medicine ,Animals ,Neoplasm Metastasis ,Receptors, Immunologic ,Cell adhesion ,chemistry.chemical_classification ,Mice, Inbred BALB C ,Oligopeptide ,biology ,medicine.disease ,Molecular biology ,In vitro ,Fibronectin ,Oncology ,Biochemistry ,chemistry ,Cell culture ,biology.protein ,Oligopeptides ,Neoplasm Transplantation - Abstract
We have analyzed the effect of the synthetic oligopeptides Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) and Gly-Arg-Gly-Glu-Ser-Pro (GRGESP), analogues to the fibronectin cell-binding sequence, on the formation of experimental lung metastasis. SR-BALB were injected alone or in conjunction with GRGDSP or GRGESP in the tail vein of BALB/c mice. Co-injection with GRGESP reduced by approximately 70% the number of metastatic colonies per mouse. However, co-injection with the closely related peptide GRGDSP, containing the conservative substitution Glu/Asp, did not affect metastatic behavior. GRGESP peptide anti-metastatic activity was not due to a toxic effect on tumor cells or on mice. In vitro adhesion assays testing for a possible effect of the peptide on cell-matrix interactions indicated that the GRGESP peptide did not affect cell adhesion to the matrix proteins tested.
- Published
- 1989
22. Characterization of stable spontaneous metastatic variant lines of RSV-transformed mouse fibroblasts
- Author
-
Bretti S and Di Renzo Mf
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Plating efficiency ,Fibrosarcoma ,Biology ,Avian sarcoma virus ,Cell Line ,Agar plate ,Mice ,In vivo ,medicine ,Animals ,Tissue Distribution ,Neoplasm Metastasis ,Mice, Inbred BALB C ,Rous sarcoma virus ,Fibroblasts ,Cell Transformation, Viral ,medicine.disease ,biology.organism_classification ,Molecular biology ,In vitro ,Culture Media ,Cell Transformation, Neoplastic ,Avian Sarcoma Viruses ,Oncology ,Injections, Intravenous ,Female ,Sarcoma, Experimental ,Sarcoma - Abstract
The correlation between metastatic potential and a series of biological properties was investigated in two mouse fibrosarcoma lines (SR-BALB and B77-3T3), transformed by different strains of Rous sarcoma virus (RSV). In the absence of selective pressure the metastatic potential was different in the two lines. The SR-BALB sarcoma did produce both spontaneous metastases from s.c. site and i.v. lung colonization with a high incidence (respectively in 60% and 80% of treated animals). Conversely, the metastatic incidence of the B77-3T3 sarcoma was much lower. Differences in lung implantation between the two lines turned out to be even greater when the number of colonies growing in the lung was evaluated. Organ distribution of cells after i.v. injection, tumorigenicity, growth rate in vivo and in vitro, plating efficiency in liquid medium and cloning efficiency in semi-solid agar medium were evaluated in the two lines. A strict correlation was found only between the metastatic potential and the capability of growth in 0.6% ("hard") agar. Such a correlation was supported by the isolation in "hard" agar of highly metastasizing subclones of the low-metastasizing B77-3T3 line.
- Published
- 1982
23. Inhibition of experimental metastasis of murine fibrosarcoma cells by oligopeptide analogues to the fibronectin cell binding site
- Author
-
Bretti, S., Neri, P., LUISA LOZZI, Rustici, M., Comoglio, P., Giancotti, F., and Tarone, G.
- Published
- 1989
24. Treatment of N2-3 pulmonary carcinoma. Preoperative radio-chemotherapy | TRATTAMENTO DEL CARCINOMA POLMONARE N2-3. RADIO-CHEMIOTERAPIA PREOPERATORIA
- Author
-
oscar bertetto, Boidi Trotti, A., Bretti, S., Casadio, C., Clerico, M., Gabriele, A. M., Giobbe, R., Oliaro, A., and Seroni, V. T.
25. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer
- Author
-
Scagliotti, G. V., Fossati, R., Torri, V., Crinò, L., Giuseppe Giaccone, Silvano, G., Martelli, M., Clerici, M., Cognetti, F., Tonato, M., Liguori, G., Nittolo, G., Vasta, M., Curcio, C., Borasio, P., Dogliotti, L., Angeletti, C. A., Conte, P. F., Laddaga, M., Rebecchini, S., Spagnesi, S., Lewinski, T., Salvati, F., Marinis, F., Altieri, A., Giordano, F., Puglisi, G., Cipriani, A., Favaretto, A., Fiorentino, M., Giampaglia, G., Loreggian, L., Zuin, R., Jassem, J., Ukmar, R., Buffoni, A., Puricelli, C., Talmassons, G., Morelli, A., Boidi Trotti, A., Bretti, S., Maggi, G., Mussa, A., Sannazzari, G. L., Baldi, S., Ricardi, U., Ruffini, E., Bruni, G., Gridelli, C., Checcaglini, F., Latini, P., Maranzano, E., Todisco, T., Santo Antonio, A., Terzi, A., Pavia, G., Sartirana, A., Ottoni, D., Fontanili, M., Sturani, C., Aiello, L. M., Barbera, S., Baracco, F., Cinquegrana, A., Felletti, R., Scolaro, T., Serrano, J., Felci, U., Manente, P., Drings, P., Zannini, P., Villa, E., Bordone, N., Tordiglione, M., Bandera, M., Fioretti, M., Roviaro, G., Bianco, A. R., Ferrante, G., Rossi, A., Sodano, A., Boni, C., Covacev, L., Lodini, V., Espana, P., Belloni, P. A., Soresi, E., Borghini, U., Cimino, G., Leoni, M., Ravini, M., Luporini, G., Todeschini, G., Campioni, N., Facciolo, F., and Clini, V.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Vindesine ,Mitomycin ,Gastroenterology ,Disease-Free Survival ,Drug Administration Schedule ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Odds Ratio ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Progression-free survival ,Lung cancer ,Survival analysis ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,business.industry ,Patient Selection ,Hazard ratio ,Middle Aged ,medicine.disease ,Survival Analysis ,Chemotherapy regimen ,Surgery ,Log-rank test ,Treatment Outcome ,Italy ,Oncology ,Chemotherapy, Adjuvant ,Multivariate Analysis ,Disease Progression ,Patient Compliance ,Female ,Cisplatin ,business ,medicine.drug - Abstract
Background: Surgery is the primary treatment for patients with stage I, II, or IIIA non-small-cell lung cancer (NSCLC). However, long-term survival of NSCLC patients after surgery alone is largely unsatisfactory, and the role of adjuvant chemotherapy in patient survival has not yet been established. Methods: Between January 1994 and January 1999, 1209 patients with stage I, II, or IIIA NSCLC were randomly assigned to receive mitomycin C (8 mg/m 2 on day 1), vindesine (3 mg/m 2 on days 1 and 8), and cisplatin (100 mg/m 2 on day 1) every 3 weeks for three cycles (MVP group; n = 606) or no treatment (control group; n = 603) after complete resection. Randomization was stratified by investigational center, tumor size, lymph-node involvement, and the intention to perform radiotherapy. The primary endpoint was overall survival and secondary endpoints were progression-free survival and toxicity associated with adjuvant treatment. Survival curves were analyzed using the log-rank test. All statistical tests were two-sided. Results: After a median follow-up time of 64.5 months, there was no statistically significant difference between the two patient groups in overall survival (hazard ratio = 0.96, 95% confidence interval = 0.81 to 1.13; P = .589) or progression-free survival (hazard ratio = 0.89, 95% confidence interval = 0.76 to 1.03; P = .128). Only 69% of patients received the three planned cycles of MVP. Grades 3 and 4 neutropenia occurred in 16% and 12%, respectively, of patients in the MVP arm. Radiotherapy was completed by 65% of patients in the MVP arm and by 82% of patients in the control group. In the multivariable analysis, only disease stage and sex were associated with survival. Conclusion: This randomized trial failed to prospectively confirm a statistically significant role for adjuvant chemotherapy in completely resected NSCLC. Given the poor compliance with the MVP regimen used in this study, future studies should explore more effective treatments.
26. Expression of the Met/HGF receptor in normal and neoplastic human tissues
- Author
-
Di Renzo, M. F., Narsimhan, R. P., Olivero, M., Bretti, S., Giordano, S., Medico Gaglia, E. P., Zara, P., and Paolo Comoglio
27. Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes
- Author
-
Paolo Comoglio, Prat, M., and Bretti, S.
- Subjects
Sarcoma, Avian ,Epitopes ,Mice ,Mice, Inbred BALB C ,Animals ,Picryl Chloride ,T-Lymphocytes, Helper-Inducer ,Cyclophosphamide ,Haptens ,Neoplasm Transplantation ,Spleen ,Research Article ,T-Lymphocytes, Cytotoxic - Abstract
Previous work from this laboratory has shown that preimmunization of syngeneic hosts with Rous sarcoma virus (RSV)-transformed cells elicits a strong immune response against the growth of transplantable RSV sarcomas, mediated by T lymphocytes expressing the surface phenotype of helper cell precursors (Prat, Di Renzo & Comoglio, 1983). This paper shows that anti-tumour immunity may be elicited in tumour-bearing animals by triggering an experimentally pre-amplified T-helper cell population at the site of tumour growth. Mice were treated with cyclophosphamide (which inactivates suppressor T cells) followed by skin sensitization to trinitrochlorobenzene (TNCB) according to a protocol that has been shown to induce an appreciably amplified generation of trinitrophenyl (TNP)-reactive helper T cells (Fujiwara et al., 1984). Five weeks after TNCB painting, mice were transplanted s.c. with a lethal dose of RSV-induced syngeneic sarcoma cells; the injection at the tumour site of TNCB induced the regression of the tumour in mice in which the TNP-helper cell population has been amplified, but not in controls, including those injected with a non-related hapten or sensitized to TNCB without inactivation of suppressors.
28. Overexpression and Ampliffcation of the Met/HGF Receptor Gene during the Progression of Colorectal Cancer
- Author
-
Di Renzo, M. F., Olivero, M., Bretti, S., Bottardi, S., Giordano, S., Paolo Comoglio, Giacomini, A., Plebani, M., Porte, H., Chastre, E., Gespach, C., Mirossay, L., and Nordlinger, B.
29. Combination chemotherapy with Cisplatin (CDDP) and Adriamycin (ADM) plus immunotherapy with interferon (IFN) alfa-2b in malignant pleural mesothelioma (MPM): results of a phase II trial of the Italian Group on Rare Tumors (GITR) and Italian Lung Cancer Task Force (FONICAP)
- Author
-
Parra, H.Soto, Bretti, S., Ardizzoni, A., Tixi, L., Latteri, F., Gravina, A., Lionetto, R., Bruzzi, P., Santoro, A., and Rosso, R.
- Published
- 1999
- Full Text
- View/download PDF
30. An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor
- Author
-
Bretti, S., Gilleece, M.H., Kamthan, A., Fitzsimmons, L., Hicks, F., Rowlands, M., Bishop, P., Picardo, A.-M., Dexter, T.M., and Scarffe, J.H.
- Published
- 1996
- Full Text
- View/download PDF
31. Combined regimen of cisplatin (CDDP), adriamycin (ADM) and a-2b interferon (IFN) in the treatment of advanced malignant pleural mesothelioma (MPM): A phase II multicenter trial of the Italian Group on Rare Tumors and Italian Lung Cancer Task Force (FONICAP)
- Author
-
Santoro, A., Tixi, L., Parra, H. J. Soto, Ardizzoni, A., Latteri, F., Bretti, S., Gravina, A., Lionetto, R., Bruzzi, P., and Rosso, R.
- Published
- 2000
- Full Text
- View/download PDF
32. 853 Ifosfamide in continuous infusion: The pharmacokinetic profile in patients with soft tissue sarcomas
- Author
-
Comandone, A., Frustaci, S., Leone, L., Santoro, A., Oliva, C., Bretti, S., verusio, C., Colussi, A.M., and Bumma, C.
- Abstract
Ifosfamide, an oxazophosphorin compound, active in mesenchimal tumours has recently been used at high doses (14–18 g/sqm) in order to increase the number of responses. Continuous infusion (C.L) of Ifosfamide probably decreases toxicity and increases the therapeutic window of the drug. Bone marrow and renal toxicities seem to be modified greatly by C.L.. Aim of our study has been to characterize the pharmacokinetic drug profile during C.L high dose-fosfamide (HD-IFO). From April to December 1994, 9 patients (pts) with advanced soft tissue sarcomas, 5 pts with osteosarcomas and I pts with Ewing's sarcoma with normal liver and renal function, treated with C.I. HD-IFO (14g/sqm. over 4 days) and Mesna contemporary infusion, entered into the study. 33 chemotherapy courses were administered (range 1–4, mean 2.2). Pts were submitted to blood sampling previous starting of infusion, and 12, 24,48,72,96, 100, 104, 114, and 120 hours after treatment beginning. Plasma samples were stored at 0°C. Chemical analysis was perfonned using HPLC. Maximum concentration of the drug was observed at 24th hour (C24: 61.5±21.9/μg/ml) while decreased pseudo-steady rate levels were reached after 70–80 hours (Css: 28.3 ± 11.5 μg/ml). Tenninal half life was 3.2±0.4 hours; AVC (following trapezoidal rule) was 3654±1222mg/l. × hour. Median Clearances (total dose/AVC) was 7.14±3.31/h. At the second or following cycles a relevant reduction of Tl/2 and AVC (–20% and –25%) due to enzymatic auto induction was observed. In confront with Ifosfamide administration at the same doses but in 1 hour infusion we observed that C.I. leads to a higher AUC (3650 vs. 1230) to a shorter Tl/2 (3.2 h. vs. 5.9 h.) and to a relevant increase of total clearance (7.14 vs. 3.9).This significant difference in pharmacokinetic profile can explain the different spectrum of activity between the two manners of administration.
- Published
- 1995
- Full Text
- View/download PDF
33. 1157 CMV and CaMV in the treatment of advanced bladder cancer
- Author
-
Berteuo, O., Valle, A., Fanchini, L., Comandone, A., Bretti, S., and Bumma, C.
- Abstract
From June 1992 to March 1995,28 patients (pts) with advanced bladder cancer were treated with CMV cytostatic regimen (14 pts; day 1: methotrexate 40 mg/m2e.v., vinblastine 4 mg/m2e.v.; day 2: cisplatin 90 mg/m2e.v.; day 8 =day 1; every 21 days) or with CaMV schedule, if serum creatinine was1. 5 mg/dl (14 pts; cisplatin substituted by carboplatin, according to renal function, following Calvert formula; every 28 days).Pts’ characteristics were: 23 males, 5 females; median age: 62.5 (range 49–76) median performance status (ECOG): 1 (range 0–2). Sites of disease involvement: locoregional spreading in 13 pts; nodal metastases (mts) in 15 pts; pulmonary mts in 4 pts; hepatic mts in 3 pts; bone mts in 1 patient (pt).Total number of administered cycles was 107 (median number of cycles per pt: 4; range 1–8). Grade 3 toxicity was: nausea and vomiting in 2 pts; anemia in 5 pts; leukopenia in 3 pts; thrombocytopenia in 2 pts; stomatitis in 3 pts. No grade 4 toxicity was reported.25 pts were evaluable for the response; we observed: 3 (12%) complete remissions (CR), 8 (32%) partial remissions (PR), 4 (16%) stable diseases and 10 (40%) prog ressive diseases.Overall response rate was good (CR+PR=44%) and toxicity was manageable and reversible.
- Published
- 1995
- Full Text
- View/download PDF
34. IntrapleuralrIL-2 pleural effusions due to malignant mesothelioma
- Author
-
Castapneto, B., Botta, M., Degiovanni, D., Bretti, S., and Mutti, L.
- Published
- 1994
- Full Text
- View/download PDF
35. Adriamycin and ifosfamide combination regimen in the treatment of advanced soft tissues sarcomas
- Author
-
Comandone, A., Mandolesi, C., Bretti, S., Bertetto, O., Clerico, M., and Bumma, C.
- Published
- 1993
- Full Text
- View/download PDF
36. Carboplatin and fluorouracil in cervix tumors
- Author
-
Bertetto, O., Clerico, M., Fanchini, L., Coaandone, A., Bretti, S., and Buana, C.
- Published
- 1993
- Full Text
- View/download PDF
37. Granulocyte colony stimulating factor (G-CSF) activity in prevention of infections in neutropenic patients
- Author
-
Comandone, A., Berardo, R., Bretti, S., Bertetto, O., Clerico, M., and Bumma, C.
- Published
- 1993
- Full Text
- View/download PDF
38. Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura
- Author
-
Alberto Oliaro, Luigia Macrì, Anna Sapino, Sofia Asioli, Sergio Bretti, Pier Luigi Filosso, Paolo Rovea, Paraskevas Lyberis, Enrico Ruffini, Filosso PL, Asioli S, Ruffini E, Rovea P, Macri' L, Sapino A, Bretti S, Lyberis P, and Oliaro A
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Solitary fibrous tumor ,medicine.medical_treatment ,Solitary fibrous tumour ,Postoperative radiotherapy ,Prognostic factors ,X ray computed ,medicine ,Humans ,Aged ,Outcome ,Prognostic factor ,Radiotherapy ,business.industry ,Respiratory disease ,Cancer ,medicine.disease ,Solitary Fibrous Tumor, Pleural ,Radiation therapy ,Oncology ,Pleura ,Female ,Surgery ,Tomography, X-Ray Computed ,business ,Radical resection - Abstract
Solitary Fibrous Tumours (SFTs) of the pleura are rare neoplasms, with unpredictable biological behaviour. Although usually benign, malignant SFTs are described, and they are often associated with large, necrotic and locally invasive tumours. Radical resection represents the treatment of choice in all cases; recurrences are uncommon, and redo-surgery should be considered. The case of a giant, invasive, radically resected malignant SFT, is described. The role of postoperative radiotherapy, to reduce the risk of recurrence, is also discussed.
- Published
- 2009
39. Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes
- Author
-
Alessandra Beano, Daniele Generali, M.A. Polimeni, Oscar Alabiso, Federico Castiglione, S Bonardi, Mara Ardine, Alfredo Berruti, Oscar Bertetto, Alberto Bottini, Michela Donadio, S Bretti, Marinella Mistrangelo, Donadio, M., Ardine, M., Berruti, A., Beano, A., Bottini, A., Mistrangelo, M., Bonardi, S., Castiglione, F., Generali, D., Polimeni, M. A., Bretti, S., Alabiso, O., and Bertetto, O.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Anthracycline ,Transcription, Genetic ,Green Fluorescent Proteins ,Antigen-Presenting Cells ,HLA-A24 Antigen ,Breast Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Deoxycytidine ,Metastasis ,Capecitabine ,Interferon-gamma ,Breast cancer ,Genes, Reporter ,Internal medicine ,Weekly cisplatin ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Anthracyclines ,RNA, Messenger ,Neoplasm Metastasis ,Cisplatin ,Taxane ,HLA-A Antigens ,business.industry ,Remission Induction ,General Medicine ,Dendritic Cells ,medicine.disease ,Flow Cytometry ,Metastatic breast cancer ,Treatment Outcome ,Microscopy, Fluorescence ,Disease Progression ,Leukocytes, Mononuclear ,Taxoids ,Fluorouracil ,Immunotherapy ,Anthracycline Taxane Capecitabine Cisplatin Metastatic breast cancer ,business ,medicine.drug - Abstract
Background: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is challenging. This study evaluated the activity and safety of a combination of cisplatin and capecitabine in this setting. Patients and Methods: Thirty-nine consecutive patients entered the study. All had experienced failures or relapse after previous treatment with anthracyclines and taxanes plus/minus other chemotherapeutic regimens. The present treatment consisted of intravenous cisplatin 20 mg/m2 every week for 6 weeks, followed by 1 week of rest, and oral capecitabine 1,000 mg/m2 twice daily for 14 days, followed by a 7-day rest period. Results: Objective response was obtained in 14 patients (35.9%), with complete remission in 3 (7.7%). Median time to progression was 5.2 months and survival was 10.9 months in the entire population and 8.7 and 16.5 months in the responding patients, respectively. The dose-limiting toxicity for the regimen was leucopenia, while gastrointestinal discomfort was the most frequent cause of capecitabine reduction or delay. Conclusions: The cisplatin and capecitabine combination regimen is active and manageable. It seems to be non-cross resistant to anthracyclines and taxanes.
- Published
- 2005
40. "Green Oncology": the Italian medical oncologists' challenge to reduce the ecological impact of their clinical activity.
- Author
-
Bretti S, Porcile G, Romizi R, Palazzo S, Oliani C, Crispino S, and Labianca R
- Subjects
- Delivery of Health Care standards, Humans, Italy, Medical Oncology standards, Neoplasms prevention & control, Primary Prevention, Delivery of Health Care trends, Medical Oncology trends, Neoplasms therapy
- Abstract
For decades Western medicine has followed a biomedical model based on linear thinking and an individualized, disease-oriented doctor-patient relationship. Today this framework must be replaced by a biopsychosocial model based on complexity theory and a person-oriented medical team-patient relationship, taking into account the psychological and social determinants of health and disease. However, the new model is already proving no longer adequate or appropriate, and current events are urging us to develop an ecological model in which the medical team takes into account both individual illness and population health as a whole, since we are all part of the biosphere. In recent years, the rising costs of cancer treatment have raised a serious issue of economic sustainability. As the population of our planet, we now need to rapidly address this issue, and everyone of us must try to reduce their ecological footprint, measured as CO2 production. Medical oncologists need to reduce the ecological footprint of their professional activity by lowering the consumption of economic resources and avoiding environmental damage as much as possible. This new paradigm is endorsed by the Italian College of Hospital Medical Oncology Directors (CIPOMO). A working group of this organization has drafted the "Green Oncology Position Paper": a proposal of Italian medical oncology (in accordance with international guidelines) that oncologists, while aiming for the same end results, make a commitment toward the more appropriate management of health care and the careful use of resources in order to protect the environment and the ecosphere during the daily exercise of their professional activities.
- Published
- 2014
- Full Text
- View/download PDF
41. Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
- Author
-
Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E, Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, and Zanon E
- Subjects
- Carboplatin administration & dosage, Cisplatin administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Humans, Neoplasm Staging, Paclitaxel administration & dosage, Radiotherapy, Adjuvant statistics & numerical data, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung therapy, Chemotherapy, Adjuvant statistics & numerical data, Health Care Surveys, Lung Neoplasms therapy
- Abstract
Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤ 1). Post-operative radiotherapy (RT) is optional for pN2 tumours., Patients and Methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail., Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage IIA, IIB, IIIA, and IIIB disease, respectively and 14% in stage IB disease. Stage, PS, and age are taken into consideration evaluating adjuvant approach by 97, 95 and 73%, respectively. Cisplatin-vinorelbine (64%) and cisplatin-gemcitabine (33%), for 4 cycles (81%), are the preferred regimens, while 32% use different regimens. Ninety-two percent indicate RT in pN2 disease and/or positive resection margins. Real Number of patients Needed to Treat (NNT) is probably not completely known/understood and/or used by physicians., Conclusions: A substantial adherence between clinical daily practice in Italy and scientific progresses is described in this paper, even with some discordances regarding the most appropriate adjuvant chemotherapy regimen., (Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
42. Radical resection of a giant, invasive and symptomatic malignant Solitary Fibrous Tumour (SFT) of the pleura.
- Author
-
Filosso PL, Asioli S, Ruffini E, Rovea P, Macri' L, Sapino A, Bretti S, Lyberis P, and Oliaro A
- Subjects
- Aged, Female, Humans, Solitary Fibrous Tumor, Pleural diagnostic imaging, Tomography, X-Ray Computed, Solitary Fibrous Tumor, Pleural pathology, Solitary Fibrous Tumor, Pleural surgery
- Abstract
Solitary Fibrous Tumours (SFTs) of the pleura are rare neoplasms, with unpredictable biological behaviour. Although usually benign, malignant SFTs are described, and they are often associated with large, necrotic and locally invasive tumours. Radical resection represents the treatment of choice in all cases; recurrences are uncommon, and redo-surgery should be considered. The case of a giant, invasive, radically resected malignant SFT, is described. The role of postoperative radiotherapy, to reduce the risk of recurrence, is also discussed.
- Published
- 2009
- Full Text
- View/download PDF
43. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
- Author
-
Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, and Sinaccio G
- Subjects
- Adult, Aged, Anemia chemically induced, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin administration & dosage, Cisplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neutropenia chemically induced, Survival Analysis, Thrombocytosis chemically induced, Treatment Outcome, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Mesothelioma drug therapy, Pleural Neoplasms drug therapy
- Abstract
Aims of this study were to evaluate the activity and toxicity of gemcitabine and cisplatin combination in malignant pleural mesothelioma (MPM). Patients with histologically proven MPM, < 75 years of age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) < or = 2, and measurable MPM were eligible. Patients received gemcitabine 1250 mg/m intravenously on days 1 and 8 and cisplatin 75 mg/m on day 2, every 21 days, for a maximum of 6 cycles. From May 1999 to May 2001, 35 chemonaive patients (median age, 61 years) were enrolled. A total of 177 cycles were administered (median 5 cycles; range 1 to 6). One patient was not evaluable for response and toxicity. Nine (26%) patients had partial responses, 11 (32%) patients had progressive disease, and 14 (41%) stable disease. Median survival for all patients was 13 months. Median progression-free survival was 8 months. Grade 3 (World Health Organization) nausea and vomiting occurred in 35% of patients. Grade 3/4 anemia, grade 3/4 thrombocythemia, and grade 3/4 neutropenia were assessed in 24%, 52%, and 61% of patients, respectively. All other side effects were mild. In conclusion, gemcitabine-cisplatin combination seems to be moderately active in MPM. Furthermore, at this dose and schedule, the toxicity profile could be acceptable.
- Published
- 2005
- Full Text
- View/download PDF
44. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature.
- Author
-
Filosso PL, Actis Dato GM, Ruffini E, Bretti S, Ozzello F, and Mancuso M
- Subjects
- Adult, Antineoplastic Agents, Hormonal therapeutic use, Biomarkers, Tumor blood, Carcinoma, Neuroendocrine diagnosis, Chemotherapy, Adjuvant, Chromogranin A, Chromogranins blood, Combined Modality Therapy, Humans, Magnetic Resonance Imaging, Male, Mediastinal Neoplasms diagnosis, Mediastinal Neoplasms therapy, Octreotide therapeutic use, Phosphopyruvate Hydratase blood, Radiotherapy, Adjuvant, Receptors, Somatostatin analysis, Thoracotomy, Thymus Neoplasms diagnosis, Tomography, X-Ray Computed, Carcinoma, Neuroendocrine therapy, Thymus Neoplasms therapy
- Published
- 2004
- Full Text
- View/download PDF
45. Supportive care in patients with advanced non-small-cell lung cancer.
- Author
-
Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S, Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P, Gridelli C, Rossi A, Barletta E, Barzelloni ML, Signoriello G, Bilancia D, Dinota A, Rosati G, Germano D, Lamberti A, Pontillo V, Brancacio L, Crispino C, Esposito M, Battiloro C, Tufano G, Cioffi A, Guardasole V, Angelini V, Guidetti G, Barbera S, Renda F, Romano F, Volpintesta A, Robbiati SF, Sannicolò M, Filipazzi V, Esani G, Gambaro A, Ferrario S, Tinessa V, Caprio MG, Zonato S, Cabiddu M, Raina A, Veltri E, D'Aprile M, Pistillucci G, Porcile G, Ostellino O, Vinante O, Azzarello G, Gebbia V, Borsellino N, Testa A, Gasparini G, Morabito A, Gattuso D, Romito S, Carrozza F, Fava S, Calcagno A, Grimi E, Bertetto O, Ciuffreda L, Parello G, Maiorino L, Santoro A, Santoro M, Failla G, Aiello RA, Bearz A, Sorio R, Scalone S, Clerici M, Bollina R, Belloni P, Sacco C, Sibau A, Adamo V, Altavilla G, Scimone A, Spatafora M, Bellia V, Hopps MR, Monfardini S, Favaretto A, Stefani M, Corradini GM, Pavia G, Scagliotti G, Novello S, Selvaggi G, Tonato M, Darwish S, Michetti G, Belometti MO, Labianca R, Quadri A, De Marinis F, Migliorino MR, Martelli O, Colucci G, Galetta D, Giotta F, Isa L, Candido P, Rossi N, Calandriello A, Ferraù F, Malaponte E, Barni S, Cazzaniga M, Gebbia N, Valerio MR, Belli M, Colantuoni G, Capuano MA, Angiolillo M, Sollitto F, Ardizzoia A, Luporini G, Locatelli MC, Pari F, Aitini E, Pedicini T, Febbraro A, Zollo C, Di Costanzo F, Bartolucci R, Gasperoni S, Gaion F, Palazzolo G, Galligioni E, Caffo O, Cortesi E, D'Auria G, Curcio C, Vasta M, Bumma C, Celano A, Bretti S, Nettis G, Anselmo A, Mattioli R, Nisticò C, Aschelter A, and Foa P
- Subjects
- Adult, Aged, Aged, 80 and over, Aging, Antiemetics therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung secondary, Cisplatin administration & dosage, Deoxycytidine administration & dosage, Female, Humans, Lung Neoplasms pathology, Lung Neoplasms secondary, Male, Middle Aged, Palliative Care, Quality of Life, Randomized Controlled Trials as Topic, Survival Rate, Vinblastine administration & dosage, Vinorelbine, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Deoxycytidine analogs & derivatives, Lung Neoplasms drug therapy, Vinblastine analogs & derivatives
- Abstract
The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.
- Published
- 2003
- Full Text
- View/download PDF
46. Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II study.
- Author
-
Bretti S, Manzin E, Loddo C, Berruti A, Bombaci S, Vellani G, and Celano A
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Cisplatin administration & dosage, Cisplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Deoxycytidine analogs & derivatives, Lung Neoplasms drug therapy
- Abstract
Background: Lung cancer is the leading cause of cancer death in men worldwide; most cases are not suitable for radical surgery at diagnosis and palliative treatment remains the primary goal of therapy. Cisplatin and gemcitabine are among the most active cytotoxic agents for the treatment of non-small cell lung cancer (NSCLC): they have non-overlapping toxicity and preclinical studies have demonstrated their potential synergistic interaction., Patients and Methods: The aims of the present study were to assess the activity and tolerability of cisplatin 80 mg/m2 on day 1, combined with gemcitabine 1000 mg/m2 on days 1 and 8, administered every 3 weeks. A total of 46 consecutive patients with advanced NSCLC entered this study; all of them were evaluable for toxicity and for activity., Results: According to an intent-to-treat analysis, 15 patients attained a partial response (33%), 9 (20%) obtained a disease stabilisation and 22 (47%) progressed. This regimen appeared to be modestly toxic, with grades 3-4 leukopenia and thrombocytopenia observed in 10% and 6% of cases respectively; grade 3 vomiting appeared in 12 patients (26%) and grade 3 mucositis in 1 patient. The median time-to-progression and overall survival were 200 and 400 days, respectively., Conclusion: Our study of gemicitabine + cisplatin on stage IV NSCLC patients achieved favourable results in terms of toxicity and overall survival.
- Published
- 2002
47. Low dose carboplatin (AUC 4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: a single institution phase II study.
- Author
-
Bretti S, Manzin E, Celano A, Ritorto G, Loddo C, and Berruti A
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Area Under Curve, Carboplatin administration & dosage, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Disease Progression, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Survival Rate, Time Factors, Vinblastine administration & dosage, Vinorelbine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin blood, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Vinblastine analogs & derivatives
- Abstract
Platinum compounds and vinorelbine (VNB) are active in the treatment of non-small cell lung cancer (NSCLC), but moderate toxicity has been reported. The aims of the present study were to assess activity and tolerability of low dose carboplatin (CBDCA): 4.5 AUC according to Calvert formula on day 1, combined with vinorelbine: 25 mg/m2 on days 1 and 8, administered every 4 weeks. Eighty-five advanced NSCLC patients entered the study; all of them were evaluable for toxicity and 83 were evaluable for activity. According to an intent to treat analysis, 26 patients attained a partial response (30.5%; 95% CI 20.5-40.5), 27 (31.7%) obtained a disease stabilization and 30 (35%) progressed. This regimen appeared to be modestly toxic, grade 3-4 leukopenia and thrombocytopenia were observed in less than 5% of cases and grade 2 neuropathy in 10% of cases. Median time to progression and overall survival were 7 and 9 months, respectively. In conclusion, low dose CBDCA (administered following Calvert's formula) and VNB combination is an active and very well tolerated cytotoxic regimen in the treatment of advanced NSCLC. The application of the Calvert formula may have contributed to limit the side effects related to CBDCA.
- Published
- 2001
- Full Text
- View/download PDF
48. Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas.
- Author
-
Comandone A, Bretti S, Bertetto O, Oliva C, Bergnolo P, and Bumma C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow Diseases chemically induced, Disease-Free Survival, Doxorubicin administration & dosage, Doxorubicin adverse effects, Female, Gastrointestinal Diseases chemically induced, Humans, Ifosfamide administration & dosage, Ifosfamide adverse effects, Male, Middle Aged, Remission Induction, Sarcoma mortality, Sarcoma pathology, Soft Tissue Neoplasms mortality, Soft Tissue Neoplasms pathology, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy
- Abstract
Background: Soft tissue sarcomas are infrequent tumors (up to 1% of all neoplasms) in adult patients. Treatment of advanced disease is largely unsatisfactory. Only a few drugs are active agents and combination regimens offer limited and short-lived activity. High dose chemotherapy may be administered only to limited groups of patients., Patients and Methods: We evaluated, in a phase II study, the adriamycin and ifosfamide combination regimen. The drugs were administered at 60 mg/sqm and 6 g/sqm dosage, respectively. The total number of treated patients was 42 of which 40 were evaluable., Results: We observed 6 complete responses (14% response rate) and 6 partial responses (14%). The mean survival was 6 months (median 7.6 months). Toxicity was limited and reversible., Conclusion: While high dose chemotherapy may be reserved for selected groups of patients, an adriamycin and ifosfamide combination regimen at conventional doses can be administered to the great majority of patients with suboptimal performance status or with advanced age.
- Published
- 2000
49. Phase II study of the activity and tolerability of a combined regimen of high-dose epirubicin and cisplatin in stage IIIb and IV non-small cell lung cancer.
- Author
-
Clerici M, De Marinis F, Piazza E, Frontini L, Tucci E, Barni S, Bretti S, Luporini G, and Intini C
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Cisplatin administration & dosage, Drug Administration Schedule, Epirubicin administration & dosage, Feasibility Studies, Female, Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Staging, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Aim: To explore the feasibility and activity of a combined regimen of high-dose epirubicin and cisplatin as an alternative to current treatments for non-small cell lung cancer (NSCLC)., Method: Forty-four patients with stage IIIb or IV NSCLC, median Karnofsky index 90, were enrolled. Epirubicin (60 mg/m2) was administered on days 1 and 2 and cisplatin (100 mg/m2) on day 1. Treatment was repeated every 21 days for a maximum of six cycles. A hematopoietic growth factor (G-CSF) was used only for patients reaching codified nadir count values., Results: A total of 130 cycles were administered with a mean of 2.9 cycles per patient. Of 41 assessable patients one showed a complete response and 15 had partial responses (overall response rate, 39%). Grade 3 or 4 leukopenia and grade 3 hemoglobin toxicity were seen in 40% and 14%, respectively, of the administered cycles. The most common nonhematologic toxic events were nausea and vomiting, mucositis, anorexia, and asthenia., Conclusions: This epirubicin-cisplatin regimen seemed effective and was generally well tolerated, and therefore suitable for use in an outpatient setting.
- Published
- 1998
- Full Text
- View/download PDF
50. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors.
- Author
-
Bretti S, Berruti A, Dogliotti L, Castagneto B, Bertulli R, Spadaro P, Toscano G, Astorre P, Verusio C, Lionetto R, Bruzzi P, and Santoro A
- Subjects
- Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease Progression, Epirubicin administration & dosage, Female, Humans, Interleukin-2 administration & dosage, Italy, Male, Middle Aged, Treatment Failure, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Mesothelioma drug therapy
- Abstract
The Italian Group on Rare Tumors undertook a phase II study of a combination of epirubicin and interleukin-2 in 21 chemotherapy-naive patients with malignant mesothelioma. All patients had bidimensionally measurable disease at CT scan. Treatment included Intravenous administration of epirubicin at a dose of 110 mg/m2 i.v. on day 1, and interleukin-2 at a dose of 9 MU subcutaneously from day 8 to day 12 and from day 15 to day 19. Cycles were repeated every three weeks, up to six times in the absence of progressive disease. Treatment response was evaluated after two cycles of therapy. Only one patient achieved a partial response, resulting in an overall response rate of 5% (1/21) with a median progression-free and overall survival of 5 and 10 months, respectively. Toxicity was relevant and caused treatment discontinuation in many patients. These results do not support the use of such a combination in the management of malignant mesothelioma.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.